NAC dosage regimen and different conditions refer from guidelines and micromedex
Reading File
Now I'll search the medical library and web simultaneously for NAC dosage information.
Finding Sources
Finding Sources
Searching the Web
N-acetylcysteine NAC dosage regimen different conditions guidelines Micromedex 2024 2025
Good results found. Now let me read the key textbook sections in detail and extract from the Texas HHS Micromedex-referenced monograph:
Reading File
Reading File
Reading Web Page
https://www.hhs.texas.gov/sites/default/files/documents/acet…
Excellent data gathered. Now let me get additional conditions - mucolytic/respiratory, contrast nephropathy, psychiatric, and read the forensic toxicology section for the full oral NAC regimen:
Reading File
Finding Sources
Searching the Web
NAC acetylcysteine dosage contrast nephropathy COPD mucolytic IPF renal guidelines Micromedex
I now have comprehensive data from multiple authoritative sources. Let me compile the full response:
N-Acetylcysteine (NAC) - Dosage Regimens by Condition
Sources: Harriet Lane Handbook 23e, Katzung's Pharmacology 16e, Murray & Nadel Respiratory Medicine, Goodman & Gilman, Essentials of Forensic Medicine & Toxicology 36e (2026), Micromedex Database (via Texas HHS Monograph), FDA Prescribing Information
Mechanism of Action (Brief)
NAC acts as a glutathione precursor (replenishes hepatic glutathione), direct free-radical scavenger, and mucolytic (breaks disulfide bonds in mucoproteins). Its antioxidant and anti-inflammatory properties underlie most off-label uses.
1. Acetaminophen (Paracetamol) Overdose - PRIMARY INDICATION
Most beneficial when given within 8-10 hours of overdose. Guided by the Rumack-Matthew nomogram.
Oral NAC (72-hour protocol - FDA approved)
| Dose | Amount | Timing |
|---|---|---|
| Loading dose | 140 mg/kg (max 15 g) | Single dose |
| Maintenance doses | 70 mg/kg (max 7.5 g) | Every 4 hours x 17 doses |
- Dilute to a 5% solution before administration
- Repeat dose if vomiting occurs within 1 hour of administration
- Continue until transaminases and INR have peaked and are substantially declining toward normal
Intravenous NAC (21-hour protocol - 3-bag method, FDA approved)
| Bag | Dose | Volume/Diluent | Infusion Time |
|---|---|---|---|
| Bag 1 (Loading) | 150 mg/kg (max 15 g) | 200 mL D5W (41 kg+) | 1 hour |
| Bag 2 (Second) | 50 mg/kg (max 5 g) | 500 mL D5W | 4 hours |
| Bag 3 (Third) | 100 mg/kg (max 10 g) | 1,000 mL D5W | 16 hours |
| Total | 300 mg/kg | 21 hours |
Pediatric weight-based dilution (5-20 kg): 3 mL/kg / 7 mL/kg / 14 mL/kg of diluent for bags 1/2/3 respectively.
Liver Failure Extension:
Continue the 100 mg/kg over 16-hour infusion (Bag 3 rate) until:
- Resolution of encephalopathy
- AST < 1,000 units/L
- INR < 2
Source: Harriet Lane Handbook 23e; FDA Prescribing Information (Acetylcysteine Injection); Essentials of Forensic Medicine & Toxicology 36e
2. Mucolytic - Respiratory Secretions
Inhalation (nebulization):
- 3-5 mL of 20% solution OR 6-10 mL of 10% solution via nebulizer
- Administered 3-4 times daily
- Can be given with bronchodilator pre-treatment to prevent bronchospasm
Oral (mucolytic for chronic bronchitis/COPD):
- 600 mg/day (standard dose) - most common regimen studied
- 1,200 mg/day (high dose) - used in exacerbation-prone patients
Note: Current GOLD guidelines and Goodman & Gilman do not recommend NAC routinely for COPD management, though it may reduce exacerbations in patients not on inhaled corticosteroids. Murray & Nadel reports mixed long-term data.
3. COPD - Prevention of Exacerbations (Off-label)
| Dose | Regimen | Evidence |
|---|---|---|
| 600 mg orally daily | Standard dose | 3-year RCT (BRONCUS): improved functional residual capacity; no significant change in FEV1 decline |
| 1,200 mg/day (600 mg BID) | High dose | Better exacerbation reduction, especially in patients NOT on inhaled steroids |
A recent meta-analysis (2021-2025 data) showed NAC at 600-1,200 mg/day for ≥6 months reduced exacerbation incidence by ~19% and improved cough, sputum, and dyspnea.
4. Contrast-Induced Nephropathy (CIN) Prevention (Off-label)
Standard oral protocol:
- 600 mg orally twice daily (1,200 mg/day)
- Start the day before the procedure (2 doses), continue the day of the procedure (2 doses)
- Total: 4 doses x 600 mg = 2,400 mg
- Given alongside IV hydration (0.9% NaCl 1 mL/kg/hr for 24 hrs)
High-dose oral protocol (higher-risk patients):
- 1,200 mg orally twice daily (start 24 hrs before contrast)
IV protocol (coronary angioplasty per AAFP/clinical protocols):
- 1,200 mg IV bolus before the procedure
- Then 1,200 mg orally twice daily x 48 hours post-procedure
Note: Evidence is mixed - the PRESERVE trial and some meta-analyses showed benefit, others did not. Most cardiology societies do not strongly endorse routine use, but it remains common given its safety profile.
5. Idiopathic Pulmonary Fibrosis (IPF) (Off-label)
- 1,800 mg/day in divided doses (600 mg three times daily)
- Used as adjunct to slow lung function deterioration
- The PANTHER-IPF trial showed that adding NAC to prednisone + azathioprine was harmful (increased mortality); NAC monotherapy showed no significant benefit over placebo
Source: Murray & Nadel; Fishman's Pulmonary Diseases. Not currently recommended in ATS/ERS/JRS/ALAT IPF guidelines.
6. Cystic Fibrosis
- Inhalation: 3-5 mL of 20% solution via nebulizer, 3-4 times/day (mucolytic)
- Oral: used off-label, doses variable (600-1,800 mg/day)
- Largely replaced by dornase alfa (DNase) for airway clearance in CF
7. Psychiatric Conditions (Off-label, via Micromedex)
| Condition | Dose | Notes |
|---|---|---|
| Obsessive-Compulsive Disorder (OCD) | Start 600 mg/day, double weekly to max 2,400 mg/day | Micromedex-documented off-label dose; benefits as adjunctive therapy ≥2,000 mg/day |
| Trichotillomania (TTM) | 1,200-2,400 mg/day | 12-week DBRCT showed benefit (Kaplan & Sadock) |
| Bipolar Disorder (depression phase) | 1,000-2,000 mg/day | Conflicting evidence; MADRS improvement shown in some studies |
| Substance Use Disorders / Addiction | 1,200-2,400 mg/day | Reduces cravings; evidence for cocaine, cannabis, nicotine |
| PTSD (adjunct to CBT) | 1,200 mg twice daily (2,400 mg/day) x 8 weeks | 81% reduction in cravings vs 32% placebo in one small study |
| Autism Spectrum Disorder | 900-2,700 mg/day (children) | Pilot RCT: 25% reduction in irritability scores |
Source: Texas HHS NAC Monograph (Micromedex Database); Kaplan & Sadock's Comprehensive Textbook of Psychiatry
8. Polycystic Ovary Syndrome (PCOS) (Off-label)
- 1,200 mg/day orally in divided doses
- Used as adjunct to clomiphene to improve ovulation induction
- Insulin-sensitizing and antioxidant effects proposed mechanism
9. Influenza Attenuation (Off-label)
- 600 mg orally twice daily (1,200 mg/day)
- Started before influenza season and continued throughout
- One double-blind RCT showed reduction in influenza symptoms and severity
10. Bronchiectasis (Off-label)
- 600 mg twice daily (per some guidelines for patients with copious secretions)
- International guidelines (ERS, BTS) mention use when excessive bronchial secretions are present; scientific evidence remains limited
Special Populations (Micromedex)
| Population | Guidance |
|---|---|
| Renal Impairment | No dosage adjustment required (Micromedex) |
| Hepatic Impairment | No specific adjustment; use cautiously |
| Geriatric | No specific dosage adjustment per manufacturer labeling |
| Pediatric | "Likely safe" at 900-2,700 mg/day for 8-12 weeks (Natural Medicines Database) |
| Pregnancy | "Likely safe" - crosses placenta but no fetal adverse effects; restrict to indicated use (acetaminophen toxicity) |
| Lactation | Avoid - insufficient data |
Key Safety Considerations
- Anaphylactoid reactions with IV NAC: most common during the loading dose (18% with 15-min infusion vs 14% with 60-min infusion); slow infusion rate reduces risk
- Bleeding: NAC has antiplatelet properties - use caution in bleeding disorders; discontinue 2 weeks before elective surgery
- Drug interactions: Potentiates vasodilatory effects of nitroglycerin - use caution
- Lab interference: False-positive serum chloride and urine ketone tests
- Look-alike/sound-alike: Do not confuse with L-cysteine (the amino acid)
- Oral formulation odor: Sulfurous smell may impair compliance; dilute in juice
Quick Reference Summary Table
| Condition | Route | Dose | Duration |
|---|---|---|---|
| APAP overdose (oral) | PO | 140 mg/kg load → 70 mg/kg q4h x17 | 72 hrs |
| APAP overdose (IV) | IV | 150→50→100 mg/kg (3-bag) | 21 hrs |
| Mucolytic (nebulized) | Inhaled | 3-5 mL of 20% TID-QID | As needed |
| COPD exacerbation prevention | PO | 600-1,200 mg/day | Long-term |
| Contrast nephropathy | PO | 600 mg BID x 2 days | Perioperative |
| IPF | PO | 1,800 mg/day | Off-label |
| OCD | PO | 600 mg → titrate to 2,400 mg/day | Off-label |
| PCOS (adj. clomiphene) | PO | 1,200 mg/day | Off-label |
| Influenza prevention | PO | 600 mg BID | Seasonal |
| TTM / Psychiatric | PO | 1,200-2,400 mg/day | Off-label |
This is a shared conversation. Sign in to Orris to start your own chat.